
    
      Study design Phase III, multicenter, randomized, open-label study designed to evaluate the
      clinical benefit from the drug combination RVD without immediate high-dose therapy (HDT)
      followed by lenalidomide maintenance (Arm A) versus RVD plus HDT and PBSCT followed by
      lenalidomide maintenance (Arm B).
    
  